EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Trastuzumab Deruxtecan in Metastatic Urothelial Carcinoma with NGS-Detected ERBB2 Amplification: A Four-Patient Real-World Case Series

Giuseppe Di Lorenzo, Sara Di Lorenzo iD, Antonio Verde, Oriana Strianese, Luigi Leo, Carlo Buonerba

Current Oncology · 2026

DOI: 10.3390/curroncol33080456 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Current Oncology, 2026. Verfasst von Giuseppe Di Lorenzo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, 84016 Pagani, Italy. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Trastuzumab, Immunoconjugates, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Next-generation sequencing (NGS)-detected ERBB2 amplification occurs in a subset of urothelial carcinomas, but its role as a treatment-selection marker for trastuzumab deruxtecan (T-DXd) remains uncertain.

Methods

We retrospectively reviewed four patients with metastatic urothelial carcinoma treated with T-DXd in routine practice from 2024. Treatment selection was based on NGS-detected ERBB2 amplification because HER2 immunohistochemistry and in situ hybridization were unavailable.

Results

Four men aged 65–76 years received T-DXd: one in the second line and three in the fourth or fifth line. The best radiological responses, abstracted from contemporaneous radiology reports and oncology medical records, were complete response in one patient, partial response in one, and stable disease in two. Three patients had previously received enfortumab vedotin. Documented adverse events included fatigue, anemia, diarrhea, rash, and leukopenia. No interstitial lung disease or pneumonitis was documented in the available records.

Conclusions

These observations are descriptive and hypothesis-generating. They do not establish the efficacy or safety of T-DXd or validate ERBB2 amplification as a predictive biomarker, but they support prospective evaluation of genomic ERBB2 amplification when standard HER2 testing is unavailable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesTrastuzumabImmunoconjugatesAntibodies, Monoclonal, HumanizedUrinary Bladder NeoplasmsCarcinoma, Transitional CellHumansMaleAgedHigh-Throughput Nucleotide SequencingGene AmplificationRetrospective StudiesNeoplasm MetastasisCamptothecin

Stichwörter der Autor:innen

ERBB2 amplificationHER2antibody–drug conjugatebladder cancernext-generation sequencingprecision oncologytrastuzumab deruxtecanurothelial carcinoma

Substanzen

Erb-b2 Receptor Tyrosine KinasesTrastuzumabtrastuzumab deruxtecanERBB2 protein, humanImmunoconjugatesAntibodies, Monoclonal, HumanizedCamptothecin

Autor:innen und Institutionen

  • Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, 84016 Pagani, Italy.
  • School of Medicine, UniCamillus-Saint Camillus International University of Health Sciences, 00131 Rome, Italy.
  • Associazione ORA ETS, 84134 Salerno, Italy.
  • Oncology Unit, ASL NA3 Sud, 80059 Torre del Greco, Italy.

ORCID-Profile: Sara Di Lorenzo

Zitieren

APA

Di Lorenzo, G., Di Lorenzo, S., Verde, A., Strianese, O., Leo, L., & Buonerba, C. (2026). Trastuzumab Deruxtecan in Metastatic Urothelial Carcinoma with NGS-Detected ERBB2 Amplification: A Four-Patient Real-World Case Series. Current Oncology. https://doi.org/10.3390/curroncol33080456

Vancouver

Di Lorenzo G, Di Lorenzo S, Verde A, Strianese O, Leo L, Buonerba C. Trastuzumab Deruxtecan in Metastatic Urothelial Carcinoma with NGS-Detected ERBB2 Amplification: A Four-Patient Real-World Case Series. Current Oncology. 2026. doi:10.3390/curroncol33080456

BibTeX
@article{DiLorenzo2026,
  author = {Di Lorenzo, Giuseppe and Di Lorenzo, Sara and Verde, Antonio and Strianese, Oriana and Leo, Luigi and Buonerba, Carlo},
  title = {Trastuzumab Deruxtecan in Metastatic Urothelial Carcinoma with NGS-Detected ERBB2 Amplification: A Four-Patient Real-World Case Series},
  journal = {Current Oncology},
  year = {2026},
  doi = {10.3390/curroncol33080456}
}
Kostenlos starten →